haematologica/journal of hematology vol. 88(05):may 2003 597 associated with intracellular redox changes and elevated plasma tumor necrosis factor-α concentration. Br J Haematol 1997;99:625-31. 8. G, Finazzi S, Maiolo AT. Folate measurement in patients on regular hemodialysis treatment. Am J Kidney Dis 1999; 33:492-7. 9. Trotti R, Carratelli M, Barbieri M, Micieli G, Bosone D, Rondanelli M, et ...

An 82-year-old female with a history of situs inversus totalis visited our hospital with complaints of abdominal pain and fever for 2 days. She had history of diabetes mellitus, cerebral infarction, and Alzheimer’s disease, and underwent Billroth-ll (B-II) gastrectomy due to stomach cancer 15 years previously. General appearance was acute ill looking and there was tenderness on right upper quad...

PURPOSE The Finnish Genetics of Pre-eclampsia Consortium (FINNPEC) Study was established to set up a nationwide clinical and DNA database on women with and without pre-eclampsia (PE), including their partners and infants, in order to identify genetic risk factors for PE. PARTICIPANTS FINNPEC is a cross-sectional case-control cohort collected from 5 university hospitals in Finland during 2008-...

Leishmaniasis is endemic in 88 countries throughout Africa, Asia, Europe and North and South America (Dedet et al., 2003). There are an estimated 12 million cases worldwide and there are about 1.5 million new cases of cutaneous leishmaniasis (CL) each year of which over 90% occur in Afghanistan, Algeria, Iran, Iraq, Saudi Arabia, Syria, Brazil and Peru (Ashford et al., 1992). Old World disease ...

Objective: We aimed to evaluate the effectiveness of an mEOX (modified epirubicin, oxaliplatin plus capecitabine) regimen as second line therapy after failure of mDCF (modified docetaxel, cisplatin plus fluorouracil). Methods: Gastic cancer patients for whom first-line therapy was unsuccessful and who subsequently received mEOX (epirubicin 50 mg/ m2 on day 1, oxaliplatin 85 mg/m² day 1 and cape...

Nucleus cochlear implant systems incorporate a fast-acting front-end automatic gain control (AGC), sometimes called a compression limiter. The objective of the present study was to determine the effect of replacing the front-end compression limiter with a newly proposed envelope profile limiter. A secondary objective was to investigate the effect of AGC speed on cochlear implant speech intellig...

[This corrects the article on p. 625 in vol. 55, PMID: 24719128.].